Table of Contents Author Guidelines Submit a Manuscript
Clinical and Developmental Immunology
Volume 2013, Article ID 412902, 8 pages
http://dx.doi.org/10.1155/2013/412902
Clinical Study

Immunophenotyping in BK Virus Allograft Nephropathy Distinct from Acute Rejection

1Research Institute of Nephrology, Jinling Hospital, Nanjing University Clinical School of Medicine, 305 East Zhong Shan Road, Nanjing 210002, China
2Department of Renal Transplantation, The Third Affiliated Hospital, Sun Yat-Sen University, Guangzhou 510760, China

Received 28 June 2013; Revised 22 August 2013; Accepted 27 August 2013

Academic Editor: Xian Li

Copyright © 2013 Xue Li et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. H. H. Hirsch, D. C. Brennan, C. B. Drachenberg et al., “Polyomavirus-associated nephropathy in renal transplantation: Interdisciplinary analyses and recommendations,” Transplantation, vol. 79, no. 10, pp. 1277–1286, 2005. View at Publisher · View at Google Scholar · View at Scopus
  2. H. H. Hirsch, “Polyomavirus BK nephropathy: a (re-)emerging complication in renal transplantation,” American Journal of Transplantation, vol. 2, no. 1, pp. 25–30, 2002. View at Publisher · View at Google Scholar · View at Scopus
  3. E. Ramos, C. B. Drachenberg, J. C. Papadimitriou et al., “Clinical course of polyoma virus nephropathy in 67 renal transplant patients,” Journal of the American Society of Nephrology, vol. 13, no. 8, pp. 2145–2151, 2002. View at Publisher · View at Google Scholar · View at Scopus
  4. H. H. Hirsch and J. Steiger, “Polyomavirus BK,” Lancet Infectious Diseases, vol. 3, no. 10, pp. 611–623, 2003. View at Publisher · View at Google Scholar · View at Scopus
  5. J. Trofe, H. H. Hirsch, and E. Ramos, “Polyomavirus-associated nephropathy: update of clinical management in kidney transplant patients,” Transplant Infectious Disease, vol. 8, no. 2, pp. 76–85, 2006. View at Publisher · View at Google Scholar · View at Scopus
  6. V. Nickeleit, H. K. Singh, and M. J. Mihatsch, “Polyomavirus nephropathy: morphology, pathophysiology, and clinical management,” Current Opinion in Nephrology and Hypertension, vol. 12, no. 6, pp. 599–605, 2003. View at Publisher · View at Google Scholar · View at Scopus
  7. V. Nickeleit, H. H. Hirsch, M. Zeiler et al., “BK-virus nephropathy in renal transplants—tubular necrosis, MHC-class II expression and rejection in a puzzling game,” Nephrology Dialysis Transplantation, vol. 15, no. 3, pp. 324–332, 2000. View at Google Scholar · View at Scopus
  8. L. Lespagnard, P. Cochaux, D. Larsimont, M. Degeyter, T. Velu, and R. Heimann, “Absence of Epstein-Barr virus in medullary carcinoma of the breast as demonstrated by immunophenotyping, in situ hybridization and polymerase chain reaction,” American Journal of Clinical Pathology, vol. 103, no. 4, pp. 449–452, 1995. View at Google Scholar · View at Scopus
  9. P. W. Hunt, J. N. Martin, E. Sinclair et al., “T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency vires-infected patients with sustained viral suppression during antiretroviral therapy,” Journal of Infectious Diseases, vol. 187, no. 10, pp. 1534–1543, 2003. View at Publisher · View at Google Scholar · View at Scopus
  10. G. A. Crane, D. Variakojis, S. T. Rosen, A. M. Sands, and H. H. Roenigk Jr., “Cutaneous T-cell lymphoma in patients with human immunodeficiency virus infection,” Archives of Dermatology, vol. 127, no. 7, pp. 989–994, 1991. View at Publisher · View at Google Scholar · View at Scopus
  11. J. M. Timms, A. Bell, J. R. Flavell et al., “Target cells of Epstein-Barr-virus (EBV)-positive post-transplant lymphoproliferative disease: similarities to EBV-positive Hodgkin's lymphoma,” The Lancet, vol. 361, no. 9353, pp. 217–223, 2003. View at Publisher · View at Google Scholar · View at Scopus
  12. M. Ahuja, E. P. Cohen, A. M. Dayer et al., “Polyoma virus infection after renal transplantation: use of immunostaining as a guide to diagnosis,” Transplantation, vol. 71, no. 7, pp. 896–899, 2001. View at Google Scholar · View at Scopus
  13. L. C. Racusen, K. Solez, R. B. Colvin et al., “The Banff 97 working classification of renal allograft pathology,” Kidney International, vol. 55, no. 2, pp. 713–723, 1999. View at Google Scholar
  14. L. C. Racusen, R. B. Colvin, K. Solez et al., “Antibody-mediated rejection criteria—an addition to the Banff '97 classification of renal allograft rejection,” American Journal of Transplantation, vol. 3, no. 6, pp. 708–714, 2003. View at Publisher · View at Google Scholar · View at Scopus
  15. M. Sarwal, M.-S. Chua, N. Kambham et al., “Molecular heterogeneity in acute renal allograft rejection identified by DNA microarray profiling,” New England Journal of Medicine, vol. 349, no. 2, pp. 125–138, 2003. View at Publisher · View at Google Scholar · View at Scopus
  16. Q. Sun, D. Cheng, M. Zhang, Q. He, Z. Chen, and Z. Liu, “Predominance of intraglomerular T-bet or GATA3 may determine mechanism of transplant rejection,” Journal of the American Society of Nephrology, vol. 22, no. 2, pp. 246–252, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. W. Jiqiu, C. Jinsong, C. Dongrui, Z. MingChao, J. shuming, and L. Zhi-Hong, “CD20+ B-cell infiltration is related to the time after transplant and poor prognosis of acute cellular rejection in renal transplant,” Experimental and Clinical Transplantation, 2013. View at Publisher · View at Google Scholar
  18. A. S. Weiss, J. Gralla, L. Chan, P. Klem, and A. C. Wiseman, “Aggressive immunosuppression minimization reduces graft loss following diagnosis of BK virus-associated nephropathy: a comparison of two reduction strategies,” Clinical Journal of the American Society of Nephrology, vol. 3, no. 6, pp. 1812–1819, 2008. View at Publisher · View at Google Scholar · View at Scopus
  19. C. A. Benavides, V. B. Pollard, S. Mauiyyedi, H. Podder, R. Knight, and B. D. Kahan, “BK virus-associated nephropathy in sirolimus-treated renal transplant patients: incidence, course, and clinical outcomes,” Transplantation, vol. 84, no. 1, pp. 83–88, 2007. View at Publisher · View at Google Scholar · View at Scopus
  20. H. M. Wadei, A. D. Rule, M. Lewin et al., “Kidney transplant function and histological clearance of virus following diagnosis of polyomavirus-associated nephropathy (PVAN),” American Journal of Transplantation, vol. 6, no. 5 I, pp. 1025–1032, 2006. View at Publisher · View at Google Scholar · View at Scopus
  21. E. R. Saad, B. A. Bresnahan, E. P. Cohen et al., “Successful treatment of BK viremia using reduction in immunosuppression without antiviral therapy,” Transplantation, vol. 85, no. 6, pp. 850–854, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. O. Johnston, D. Jaswal, J. S. Gill, S. Doucette, D. A. Fergusson, and G. A. Knoll, “Treatment of polyomavirus infection in kidney transplant recipients: a systematic review,” Transplantation, vol. 89, no. 9, pp. 1057–1070, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. S. Hussain, B. A. Bresnahan, E. P. Cohen, and S. Hariharan, “Rapid kidney allograft failure in patients with polyoma virus nephritis with prior treatment with antilymphocyte agents,” Clinical Transplantation, vol. 16, no. 1, pp. 43–47, 2002. View at Publisher · View at Google Scholar · View at Scopus
  24. C. B. Drachenberg, J. C. Papadimitriou, H. H. Hirsch et al., “Histological patterns of polyomavirus nephropathy: correlation with graft outcome and viral load,” American Journal of Transplantation, vol. 4, no. 12, pp. 2082–2092, 2004. View at Publisher · View at Google Scholar · View at Scopus
  25. B. M. Hall, G. A. Bishop, and G. G. Duggin, “Increased expression of HLA-DR antigens on renal tubular cells in renal transplants: relevance to the rejection response,” The Lancet, vol. 2, no. 8397, pp. 247–251, 1984. View at Google Scholar · View at Scopus
  26. F. C. Henny, J. J. Weening, and W. M. Baldwin, “Expression of HLA-DR antigens on peripheral blood T lymphocytes and renal graft tubular epithelial cells in association with rejection,” Transplantation, vol. 42, no. 5, pp. 479–483, 1986. View at Google Scholar · View at Scopus
  27. H. H. Hirsch and P. Randhawa, “BK virus in solid organ transplant recipients,” American Journal of Transplantation, vol. 9, no. supplement 4, pp. S136–S146, 2009. View at Publisher · View at Google Scholar · View at Scopus
  28. B. Celik, R. Shapiro, A. Vats, and P. S. Randhawa, “Polyomavirus allograft nephropathy: sequential assessment of histologic viral load, tubulitis, and graft function following changes in immunosuppression,” American Journal of Transplantation, vol. 3, no. 11, pp. 1378–1382, 2003. View at Publisher · View at Google Scholar · View at Scopus
  29. P. Randhawa and D. C. Brennan, “BK virus infection in transplant recipients: an overview and update,” American Journal of Transplantation, vol. 6, no. 9, pp. 2000–2005, 2006. View at Publisher · View at Google Scholar · View at Scopus
  30. G. De Bruyn and A. P. Limaye, “BK virus-associated nephropathy in kidney transplant recipients,” Reviews in Medical Virology, vol. 14, no. 3, pp. 193–205, 2004. View at Publisher · View at Google Scholar · View at Scopus
  31. H. H. Hirsch, “BK virus: opportunity makes a pathogen,” Clinical Infectious Diseases, vol. 41, no. 3, pp. 354–360, 2005. View at Publisher · View at Google Scholar · View at Scopus
  32. V. Nickeleit and M. J. Mihatsch, “Polyomavirus nephropathy in native kidneys and renal allografts: an update on an escalating threat,” Transplant International, vol. 19, no. 12, pp. 960–973, 2006. View at Publisher · View at Google Scholar · View at Scopus
  33. P. D. Acott and H. H. Hirsch, “BK virus infection, replication, and diseases in pediatric kidney transplantation,” Pediatric Nephrology, vol. 22, no. 9, pp. 1243–1250, 2007. View at Publisher · View at Google Scholar · View at Scopus
  34. D. L. Bohl and D. C. Brennan, “BK virus nephropathy and kidney transplantation,” Clinical Journal of the American Society of Nephrology, vol. 2, no. supplement 1, pp. S36–S46, 2007. View at Publisher · View at Google Scholar · View at Scopus
  35. J. A. Fishman, “BK virus nephropathy—polyomavirus adding insult to injury,” New England Journal of Medicine, vol. 347, no. 7, pp. 527–530, 2002. View at Publisher · View at Google Scholar · View at Scopus
  36. P. S. Randhawa and A. J. Demetris, “Nephropathy due to polyomavirus type BK,” New England Journal of Medicine, vol. 342, no. 18, pp. 1361–1363, 2000. View at Publisher · View at Google Scholar · View at Scopus
  37. C. B. Drachenberg, C. O. Beskow, C. B. Cangro et al., “Human polyoma virus in renal allograft biopsies: morphological findings and correlation with urine cytology,” Human Pathology, vol. 30, no. 8, pp. 970–977, 1999. View at Publisher · View at Google Scholar · View at Scopus
  38. D. N. Howell, S. R. Smith, D. W. Butterly et al., “Diagnosis and management of BK polyomavirus interstitial nephritis in renal transplant recipients,” Transplantation, vol. 68, no. 9, pp. 1279–1288, 1999. View at Google Scholar · View at Scopus
  39. W. Manitpisitkul, C. Drachenberg, E. Ramos et al., “Maintenance immunosuppressive agents as risk factors for BK virus nephropathy: a case-control study,” Transplantation, vol. 88, no. 1, pp. 83–88, 2009. View at Publisher · View at Google Scholar · View at Scopus